Mylan, Micro Labs receive FDA approval to market generic Eliquis


Shares of Mylan MYL, +0.49% are up 0.2% in premarket trading on Tuesday. The Food and Drug Administration said Monday that the company and Micro Labs Ltd., a privately held generic drugmaker, had each received approval to market generic versions of the blood-thinner Eliquis for two indications. Eliquis is co-marketed by Bristol-Myers Squibb BMY, +0.27% and Pfizer PFE, -0.48%. The medication brought in $3.1 billion in the first nine months of 2019, up from $2.5 billion in the same timeframe in 2018, for Pfizer, and $5.4 billion for BMS for the nine months ending Sept. 30, 2019, up from $4.9 billion for the nine months ending Sept. 30, 2018. More than 20 generic drugmakers sued the companies over Eliquis patents in 2017. Mylan's stock is down 27% year-to-date, while the S&P 500 SPX, +1.19% has gained 28%.